Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis.

Abstract

SPK-843, a new polyene antifungal, exhibited dose-dependent efficacy on murine pulmonary aspergillosis models. SPK-843 doses of higher than 1.0 mg/kg of body weight exhibited no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone) (1.0 mg/kg) and liposomal amphotericin B (AmBisome) (8.0 mg/kg).

• Authors: Hiroshi Kakeya, Yoshitsugu Miyazaki, Hisato Senda, Tsutomu Kobayashi, Masafumi Seki, Koichi Izumikawa, Kazunori Yanagihara, Yoshihiro Yamamoto, Takayoshi Tashiro, Shigeru Kohno
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 52 Issue 5 Pg. 1868-70 (May 2008) ISSN: 1098-6596 [Electronic] United States
• PMID: 18299412 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Antifungal Agents
• Echinocandins
• Lipopeptides
• Lipoproteins
• Polyenes
• liposomal amphotericin B
• SPA S 843
• Amphotericin B
• Micafungin

Topics

• Amphotericin B (pharmacology)
• Animals
• Antifungal Agents (pharmacology)
• Aspergillosis (drug therapy, microbiology)
• Aspergillus flavus (drug effects)
• Disease Models, Animal
• Dose-Response Relationship, Drug
• Echinocandins (pharmacology)
• Lipopeptides
• Lipoproteins (pharmacology)
• Lung Diseases, Fungal (drug therapy, microbiology)
• Male
• Micafungin
• Mice
• Polyenes (pharmacology)
• Treatment Outcome